{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:21:33Z","timestamp":1774977693961,"version":"3.50.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.contraception.2011.02.013","type":"journal-article","created":{"date-parts":[[2011,4,30]],"date-time":"2011-04-30T20:41:27Z","timestamp":1304196087000},"page":"342-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Current issues and available options in combined hormonal contraception"],"prefix":"10.1016","volume":"84","author":[{"given":"Johannes","family":"Bitzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.02.013_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/13625180903427675","article-title":"Efficacy of contraceptive methods: a review of the literature","volume":"15","author":"Mansour","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.02.013_bb0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-199512020-00002","article-title":"The combined oral contraceptive. Risks and adverse effects in perspective","volume":"12","author":"Bagshaw","year":"1995","journal-title":"Drug Saf"},{"key":"10.1016\/j.contraception.2011.02.013_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.yebeh.2006.05.002","article-title":"The impact of antiepileptic drug therapy on steroidal contraceptive efficacy","volume":"9","author":"Thorneycroft","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.contraception.2011.02.013_bb0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0010-7824(99)00109-2","article-title":"Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations","volume":"60","author":"Rosenberg","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0025","first-page":"CD003989","article-title":"20 microg versus >20 microg estrogen combined oral contraceptives for contraception (review)","volume":"2","author":"Gallo","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.02.013_bb0030","first-page":"340","article-title":"Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study","volume":"c927","author":"Hannaford","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2011.02.013_bb0035","first-page":"975","article-title":"Evolution of progestins. Focus on the novel progestin drospirenone","volume":"47","author":"Thorneycroft","year":"2002","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2011.02.013_bb0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/13625187.2010.504313","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17B-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol","volume":"15","author":"Duijkers","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.02.013_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejogrb.2009.11.001","article-title":"Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate\/dienogest): a phase III trial","volume":"149","author":"Palacios","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13625180903585431","article-title":"After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives","volume":"15","author":"Alsina","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.02.013_bb0055","first-page":"CD004695","article-title":"Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception","author":"Edelman","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.02.013_bb0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0010-7824(96)00137-0","article-title":"Shorter pill-free interval in combined oral contraceptives decreases follicular development","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0065","first-page":"261","article-title":"Hormone withdrawal symptoms in oral contraceptive users","volume":"95","author":"Sulak","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0070","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1016\/S0010-7824(98)00078-X","article-title":"Oral contraceptive estrogen dose considerations","volume":"58","author":"Kaunitz","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1067\/mob.2001.109656","article-title":"The pharmacokinetics and efficacy of different estrogens are not equivalent","volume":"184","author":"Ansbacher","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0080","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0002-9378(82)90218-6","article-title":"Comparison of pharmacodynamic properties of various estrogen formulations","volume":"144","author":"Mashchak","year":"1982","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2011.02.013_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2011.02.013_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2008.02.020","article-title":"Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins","volume":"78","author":"Goldzieher","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0100","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/0002-9378(85)90664-7","article-title":"Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol","volume":"151","author":"Goebelsmann","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.contraception.2007.01.027","article-title":"Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen","volume":"75","author":"Sitruk-Ware","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF03349013","article-title":"Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women","volume":"19","author":"Stomati","year":"1996","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.contraception.2011.02.013_bb0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0301-2115(97)02706-1","article-title":"Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women","volume":"73","author":"Basbug","year":"1997","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0120","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.metabol.2008.03.012","article-title":"Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins","volume":"57","author":"Vrablik","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.contraception.2011.02.013_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0010-7824(89)90094-2","article-title":"Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives","volume":"40","author":"Jung-Hoffmann","year":"1989","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-7824(91)90122-V","article-title":"Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months","volume":"43","author":"Dibbelt","year":"1991","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0010-7824(93)90043-7","article-title":"Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol","volume":"47","author":"Hammerstein","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000182110","article-title":"Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design","volume":"36","author":"Kuhnz","year":"1991","journal-title":"Horm Res"},{"key":"10.1016\/j.contraception.2011.02.013_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000181446","article-title":"Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design","volume":"33","author":"Kuhnz","year":"1990","journal-title":"Horm Res"},{"key":"10.1016\/j.contraception.2011.02.013_bb0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0010-7824(91)90069-R","article-title":"The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel","volume":"43","author":"Orme","year":"1991","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1530\/eje.0.1390167","article-title":"Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives\u2013results of isotope dilution mass spectrometry measurements","volume":"139","author":"Siekmann","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(01)18648-4","article-title":"Factors in human fertility and their statistical evaluation","volume":"222","author":"Pearl","year":"1933","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/sim.4780100206","article-title":"Methodological pitfalls in the analysis of contraceptive failure","volume":"10","author":"Trussell","year":"1991","journal-title":"Stat Med"},{"key":"10.1016\/j.contraception.2011.02.013_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2307\/2060159","article-title":"Application of life table techniques to measurement of contraceptive effectiveness","volume":"3","author":"Potter","year":"1966","journal-title":"Demography"},{"key":"10.1016\/j.contraception.2011.02.013_bb0175","first-page":"558","article-title":"A guide to interpreting contraceptive efficacy studies","volume":"76","author":"Trussell","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0180","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2307\/2528521","article-title":"Characteristics of a ratio used to estimate failure rates: occurrences per person-year of exposure","volume":"22","author":"Sheps","year":"1966","journal-title":"Biometrics"},{"key":"10.1016\/j.contraception.2011.02.013_bb0185","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2006.07.004","article-title":"Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone","volume":"74","author":"Ahrendt","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0190","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.contraception.2004.09.001","article-title":"Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial","volume":"71","author":"Oddsson","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0195","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1001\/jama.285.18.2347","article-title":"Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial","volume":"285","author":"Audet","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.02.013_bb0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2005.01.021","article-title":"Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception","volume":"121","author":"Urdl","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0205","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","article-title":"Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons","volume":"179","author":"Rosenberg","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0010-7824(95)00074-K","article-title":"Use and misuse of oral contraceptives: risk indicators for poor pill-taking and discontinuation","volume":"51","author":"Rosenberg","year":"1995","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2011.02.013_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003552.pub2","article-title":"Skin patch and vaginal ring versus combined oral contraceptives for contraception","volume":"23","author":"Lopez","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.02.013_bb0220","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1067\/mob.2002.121103","article-title":"Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel\/ethinyl estradiol","volume":"186","author":"Bjarnadottir","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/humrep\/deh604","article-title":"Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial","volume":"20","author":"Oddsson","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.02.013_bb0230","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/humrep\/del162","article-title":"Effects on cycle control and body weight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone","volume":"21","author":"Milsom","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.02.013_bb0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.AOG.0000164483.13326.59","article-title":"Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive","volume":"106","author":"Westhoff","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0240","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2006.03.022","article-title":"Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives","volume":"74","author":"Sabatini","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1067\/mob.2002.118844","article-title":"Transdermal contraception: evaluation of three transdermal norelgestromin\/ethinyl estradiol doses in a randomized, multicenter, dose-response study","volume":"186","author":"Dittrich","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0250","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00002512-200421130-00004","article-title":"New progestogens: a review of their effects in perimenopausal and postmenopausal women","volume":"21","author":"Sitruk-Ware","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.contraception.2011.02.013_bb0255","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/17474108.3.2.189","article-title":"Third-generation oral contraceptives: future implications of current use","volume":"3","author":"Ouzounian","year":"2008","journal-title":"Expert Rev Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0260","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.maturitas.2004.01.001","article-title":"Pharmacological profile of progestins","volume":"47","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2011.02.013_bb0265","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2165\/11532130-000000000-00000","article-title":"Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy","volume":"70","author":"Lello","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2011.02.013_bb0270","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/humupd\/5.6.721","article-title":"Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks","volume":"5","author":"Farley","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2011.02.013_bb0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0280","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0285","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1086-5802(16)31329-8","article-title":"Oral contraceptives: an update on health benefits and risks","volume":"41","author":"Borgelt-Hansen","year":"2001","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"10.1016\/j.contraception.2011.02.013_bb0290","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.295.15.1824","article-title":"The influence of estrogen on migraine: a systematic review","volume":"295","author":"Brandes","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.02.013_bb0295","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/humrep\/16.3.469","article-title":"Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol","volume":"16","author":"Roumen","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.02.013_bb0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.contraception.2005.02.002","article-title":"Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive","volume":"72","author":"Caruso","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0305","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/humrep\/deh686","article-title":"Effects of two types of hormonal contraception \u2014 oral versus intravaginal \u2014 on the sexual life of women and their partners","volume":"20","author":"Guida","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.02.013_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2008.09.066","article-title":"Sexual function in first-time contraceptive ring and contraceptive patch users","volume":"93","author":"Gracia","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2011.02.013_bb0315","first-page":"576","article-title":"A prospective, controlled study of the effects of hormonal contraception on bone mineral density","volume":"98","author":"Berenson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0320","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/archinte.1991.00400100053009","article-title":"Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group","volume":"151","author":"Kleerekoper","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.contraception.2011.02.013_bb0325","first-page":"736","article-title":"Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health","volume":"95","author":"Petitti","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0010-7824(00)00086-X","article-title":"Low-dose oral contraceptives and bone mineral density: an evidence-based analysis","volume":"61","author":"Kuohung","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0335","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0015-0282(00)00719-6","article-title":"Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study","volume":"74","author":"Lloyd","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2011.02.013_bb0340","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(98)09044-8","article-title":"Oral-contraceptive use and risk of hip fracture: a case-control study","volume":"353","author":"Michaelsson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0345","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0010-7824(03)00147-1","article-title":"Longitudinal changes in bone density in relation to oral contraceptive use","volume":"68","author":"Reed","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0350","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.contraception.2008.11.009","article-title":"Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate","volume":"79","author":"Beksinska","year":"2009","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2011.02.013_bb0355","first-page":"CD006033","article-title":"Steroidal contraceptives: effect on bone fractures in women","volume":"15","author":"Lopez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.02.013_bb0360","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jadohealth.2004.07.005","article-title":"Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls","volume":"35","author":"Cromer","year":"2004","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.contraception.2011.02.013_bb0365","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.contraception.2009.09.011","article-title":"Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study","volume":"81","author":"Massaro","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0370","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.contraception.2006.01.003","article-title":"Combined hormonal contraception and bone health: a systematic review","volume":"73","author":"Martins","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0375","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1517\/14656566.9.13.2317","article-title":"Non-contraceptive benefits of oral contraceptives","volume":"9","author":"Huber","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.contraception.2011.02.013_bb0380","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJM198703123161102","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.02.013_bb0385","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/humrep\/12.9.1851","article-title":"Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis","volume":"12","author":"Schlesselman","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.02.013_bb0390","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0065-230X(08)60801-5","article-title":"On the epidemiology of oral contraceptives and disease","volume":"49","author":"Prentice","year":"1987","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.contraception.2011.02.013_bb0395","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.23079","article-title":"Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women","volume":"122","author":"Kabat","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.contraception.2011.02.013_bb0400","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0405","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.02.013_bb0410","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.contraception.2010.04.006","article-title":"Factors affecting mortality in a large cohort study with special reference to oral contraceptive use","volume":"82","author":"Vessey","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0415","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(02)08150-3","article-title":"Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study","volume":"359","author":"Moreno","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0420","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(96)07496-X","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0425","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/0895-4356(95)00516-1","article-title":"A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception","volume":"48","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0430","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.gyobfe.2008.02.006","article-title":"Hormonal contraception and risk of venous thromboembolism: when to ask for an assessment of hemostasis? Which parameters?","volume":"36","author":"Plu-Bureau","year":"2008","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.contraception.2011.02.013_bb0435","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.163.9.1105","article-title":"Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception","volume":"163","author":"Cosmi","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.contraception.2011.02.013_bb0440","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/107602960401000308","article-title":"Effect of age on oral contraceptive-induced venous thrombosis","volume":"10","author":"Girolami","year":"2004","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.contraception.2011.02.013_bb0445","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0450","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2007-0026","article-title":"Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study","volume":"92","author":"Sitruk-Ware","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2011.02.013_bb0455","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.contraception.2006.04.005","article-title":"Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins","volume":"74","author":"White","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0460","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1592\/phco.27.2.218","article-title":"The contraceptive patch in relation to ischemic stroke and acute myocardial infarction","volume":"27","author":"Jick","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.contraception.2011.02.013_bb0465","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.contraception.2006.05.071","article-title":"Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch","volume":"74","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0470","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2007.03.003","article-title":"Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol","volume":"76","author":"Jick","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0475","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.contraception.2006.01.001","article-title":"Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0480","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0485","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2008.07.004","article-title":"Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis","volume":"78","author":"Jensen","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0490","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.thromres.2008.04.022","article-title":"Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study","volume":"123","author":"Fleischer","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2011.02.013_bb0495","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.fertnstert.2009.12.054","article-title":"Surrogate end points in women's health research: science, protoscience, and pseudoscience","volume":"93","author":"Grimes","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2011.02.013_bb0500","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0074-7742(08)00006-8","article-title":"Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management","volume":"83","author":"Dutton","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0505","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2010.06.013","article-title":"The use of hormonal contraception among women taking anticonvulsant therapy","volume":"83","author":"Gaffield","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0510","series-title":"Medical eligibility criteria for contraceptive use. 4 ed","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.contraception.2011.02.013_bb0515","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1783\/147118910793048764","article-title":"Contraception for women taking antiepileptic drugs","volume":"36","author":"O'Brien","year":"2010","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.02.013_bb0520","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0010-7824(99)00034-7","article-title":"Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women","volume":"59","author":"Oddens","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0525","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/01.AOG.0000136082.59644.13","article-title":"A comparison between the vaginal ring and oral contraceptives","volume":"104","author":"Veres","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0530","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/13625187.2010.524717","article-title":"Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use","volume":"15","author":"Merki-Feld","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.02.013_bb0535","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13625180903456930","article-title":"The use of the vaginal ring and transdermal patch among adolescent girls in Finland","volume":"15","author":"Falah-Hassani","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.02.013_bb0540","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000298338.58511.d1","article-title":"Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial","volume":"111","author":"Creinin","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0545","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.fertnstert.2009.01.071","article-title":"Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis","volume":"93","author":"Vercellini","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2011.02.013_bb0550","first-page":"577","article-title":"Prevalence of facial acne in adults","volume":"41","author":"Goulden","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0555","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","author":"Arowojolu","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.02.013_bb0560","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.contraception.2005.07.010","article-title":"Treating acne with oral contraceptives: use of lower doses","volume":"73","author":"Huber","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0565","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1529-8019.2009.01261.x","article-title":"Should dermatologists prescribe hormonal contraceptives for acne?","volume":"22","author":"Harper","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.contraception.2011.02.013_bb0570","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1139\/jpn.0828","article-title":"Premenstrual dysphoric disorder: burden of illness and treatment update","volume":"33","author":"Pearlstein","year":"2008","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.contraception.2011.02.013_bb0575","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/AOG.0b013e3181cb50b5","article-title":"Noncontraceptive uses of hormonal contraceptives. Practice Bulletin No. 110. American College of Obstetricians and Gynecologists","volume":"115","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0580","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2006.03.024","article-title":"Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraception","volume":"74","author":"Blumenthal","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0585","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bpobgyn.2007.03.023","article-title":"Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system","volume":"21","author":"Mansour","year":"2007","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0590","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.contraception.2004.04.007","article-title":"Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding","volume":"70","author":"Sulak","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0595","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/13625180701440180","article-title":"Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages","volume":"12","author":"Merki-Feld","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.02.013_bb0600","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2010.05.005","article-title":"Non-contraceptive health benefits of intrauterine hormonal systems","volume":"82","author":"Fraser","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0605","first-page":"341","article-title":"Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients","volume":"c3929","author":"Middleton","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2011.02.013_bb0610","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.contraception.2010.06.011","article-title":"Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial","volume":"83","author":"Shabaan","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0615","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1701-2163(16)34151-2","article-title":"A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia","volume":"31","author":"Endrikat","year":"2009","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.contraception.2011.02.013_bb0620","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2006.08.004","article-title":"Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg\/ethinyl estradiol 20 micro g (Loestrin 24 Fe)","volume":"75","author":"Nakajima","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0625","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0010-7824(03)00141-0","article-title":"A multicenter, randomized study of an extended cycle oral contraceptive","volume":"68","author":"Anderson","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0630","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.contraception.2005.09.010","article-title":"Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol","volume":"73","author":"Anderson","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0640","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ajog.2005.12.045","article-title":"Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial","volume":"195","author":"Anderson","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0645","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2006.07.005","article-title":"Evaluation of a continuous regimen of levonorgestrel\/ethinyl estradiol: phase 3 study results","volume":"74","author":"Archer","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.02.013_bb0650","first-page":"653","article-title":"Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial","volume":"101","author":"Miller","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0655","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1600-0412.1981.tb00038.x","article-title":"Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation","volume":"60","author":"Serup","year":"1981","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2011.02.013_bb0660","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(79)91525-3","article-title":"Natural oestrogens for oral contraception","volume":"2","author":"Serup","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.02.013_bb0665","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0940-2993(98)80034-1","article-title":"Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives","volume":"50","author":"Hoffmann","year":"1998","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.contraception.2011.02.013_bb0670","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/dmi046","article-title":"New progestagens for contraceptive use","volume":"12","author":"Sitruk-Ware","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2011.02.013_bb0675","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0378-5122(82)90064-0","article-title":"Pharmacokinetic and pharmacological features of oestradiol valerate","volume":"4","author":"Dusterberg","year":"1982","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2011.02.013_bb0680","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/14656561003724713","article-title":"Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest","volume":"11","author":"Jensen","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.contraception.2011.02.013_bb0685","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.contraception.2009.03.018","article-title":"Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinyl estradiol\/levonorgestrel","volume":"80","author":"Ahrendt","year":"2009","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:09:33Z","timestamp":1757880573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":136,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0010782411000977"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.02.013","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current issues and available options in combined hormonal contraception","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2011.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}